Development of a Curative Therapeutic Vaccine (TheraVac) for the Treatment of Large Established Tumors
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Development of a Curative Therapeutic Vaccine (TheraVac) for the Treatment of Large Established Tumors
Authors
Keywords
-
Journal
Scientific Reports
Volume 7, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-10-23
DOI
10.1038/s41598-017-14655-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses
- (2016) Kelly D Moynihan et al. NATURE MEDICINE
- Definitive activation of endogenous antitumor immunity by repetitive cycles of cyclophosphamide with interspersed Toll-like receptor agonists
- (2016) Soraya Zorro Manrique et al. Oncotarget
- The role of active vaccination in cancer immunotherapy: lessons from clinical trials
- (2015) Haydn T Kissick et al. CURRENT OPINION IN IMMUNOLOGY
- Tumor-Infiltrating Dendritic Cells in Cancer Pathogenesis
- (2015) Jo Marie Tran Janco et al. JOURNAL OF IMMUNOLOGY
- Design considerations for nanotherapeutics in oncology
- (2015) Triantafyllos Stylianopoulos et al. Nanomedicine-Nanotechnology Biology and Medicine
- The Alarmin HMGN1 Contributes to Antitumor Immunity and Is a Potent Immunoadjuvant
- (2014) F. Wei et al. CANCER RESEARCH
- Toll receptor agonist therapy of skin cancer and cutaneous T-cell lymphoma
- (2014) Auris O. Huen et al. CURRENT OPINION IN ONCOLOGY
- A Listeria Vaccine and Depletion of T-Regulatory Cells Activate Immunity Against Early Stage Pancreatic Intraepithelial Neoplasms and Prolong Survival of Mice
- (2014) Bridget P. Keenan et al. GASTROENTEROLOGY
- An optimized disaggregation method for human lung tumors that preserves the phenotype and function of the immune cells
- (2014) Jon G. Quatromoni et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer
- (2014) Julia Scheiermann et al. VACCINE
- Inactivation of tumor-specific CD8+ CTLs by tumor-infiltrating tolerogenic dendritic cells
- (2013) Hirotomo Harimoto et al. IMMUNOLOGY AND CELL BIOLOGY
- Calling cells to arms
- (2013) Emily Elert NATURE
- Antibody Therapeutics in Cancer
- (2013) M. X. Sliwkowski et al. SCIENCE
- Cancer Immunotherapy
- (2013) J. Couzin-Frankel SCIENCE
- Alarmins: awaiting a clinical response
- (2012) James K. Chan et al. JOURNAL OF CLINICAL INVESTIGATION
- Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1
- (2012) Shigeki Chiba et al. NATURE IMMUNOLOGY
- Trial Watch
- (2012) Lorenzo Galluzzi et al. OncoImmunology
- Cross-priming for antitumor CTL induced by soluble Ag + polyI:C depends on the TICAM-1 pathway in mouse CD11c+/CD8α+dendritic cells
- (2012) Masahiro Azuma et al. OncoImmunology
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer
- (2011) Stephanie K. Watkins et al. JOURNAL OF CLINICAL INVESTIGATION
- High-mobility group nucleosome-binding protein 1 acts as an alarmin and is critical for lipopolysaccharide-induced immune responses
- (2011) De Yang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Tumor-Infiltrating Programmed Death Receptor-1+ Dendritic Cells Mediate Immune Suppression in Ovarian Cancer
- (2011) J. Krempski et al. JOURNAL OF IMMUNOLOGY
- Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus
- (2011) Vincenzo Cerullo et al. MOLECULAR THERAPY
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- Programming the magnitude and persistence of antibody responses with innate immunity
- (2011) Sudhir Pai Kasturi et al. NATURE
- Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know
- (2011) Steven A. Rosenberg Nature Reviews Clinical Oncology
- Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study
- (2011) A. Carpentier et al. NEURO-ONCOLOGY
- Selective Depletion of Foxp3+ Regulatory T Cells Improves Effective Therapeutic Vaccination against Established Melanoma
- (2010) K. Klages et al. CANCER RESEARCH
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Recovery from Cyclophosphamide-Induced Lymphopenia Results in Expansion of Immature Dendritic Cells Which Can Mediate Enhanced Prime-Boost Vaccination Antitumor Responses In Vivo When Stimulated with the TLR3 Agonist Poly(I:C)
- (2009) M. L. Salem et al. JOURNAL OF IMMUNOLOGY
- Tumor-Educated CD11b high Ia low Regulatory Dendritic Cells Suppress T Cell Response through Arginase I
- (2009) Qiuyan Liu et al. JOURNAL OF IMMUNOLOGY
- Eosinophil-derived neurotoxin acts as an alarmin to activate the TLR2–MyD88 signal pathway in dendritic cells and enhances Th2 immune responses
- (2008) De Yang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Comparative methodologies of regulatory T cell depletion in a murine melanoma model
- (2008) Norimasa Matsushita et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells
- (2008) L. Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now